HS-20093 for Injection

DRUG4 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Hansoh BioMedical R&D Company

Conditions

Advanced Gastric and Gastroesophageal Junction AdenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Non-Small Cell Lung CancerProstate Cancer

Phase 1

HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

RecruitingNCT07462923

Hansoh BioMedical R&D CompanyAdvanced Gastric and Gastroesophageal Junction Adenocarcinoma

Start: 2026-01-29End: 2028-03-31Target: 40Updated: 2026-03-10

Phase 2

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

RecruitingNCT07230106

Jiangsu HengRui Medicine Co., Ltd.Prostate Cancer

Start: 2025-12-08End: 2029-12-01Target: 218Updated: 2026-03-03

A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Not yet recruitingNCT07824882

Hansoh BioMedical R&D CompanyNon-Small Cell Lung Cancer

Start: 2026-09-10End: 2029-09-30Target: 76Updated: 2026-09-17

Phase 3

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Not yet recruitingNCT07621601

Hansoh BioMedical R&D CompanyEsophageal Squamous Cell Carcinoma (ESCC)

Start: 2026-07-31End: 2032-12-31Target: 494Updated: 2026-06-02